EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of COVID-19 on Incidence, Treatment, and Survival of Patients with Hepatocellular Carcinoma in the Netherlands

Alicia Furumaya iD, Otto M van Delden, Roeland F de Wilde, Judith de Vos-Geelen, Lydia G van der Geest, Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG) and the COVID & Cancer-NL consortium

Disaster Medicine and Public Health Preparedness · 2024

DOI: 10.1017/dmp.2024.176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disaster Medicine and Public Health Preparedness, 2024. Verfasst von Alicia Furumaya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, COVID-19, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The impact of the coronavirus disease 2019 (COVID-19) on hepatocellular carcinoma (HCC) care is unclear. This study reports on HCC patterns during the COVID-19 pandemic in the Netherlands.

Methods

Patients diagnosed with HCC between 2017 and 2020 were identified from the Netherlands Cancer Registration. Monthly incidence rates were compared between 2020 and 2017–2019. Patient, tumor, process, and treatment characteristics and survival were compared between 2020 and 2017–2019, and between COVID-high (April and May 2020) and COVID-low (June and July 2020) months.

Results

The incidence of HCC was lower in May 2020 (IRR 0.56, P = 0.001) and higher in June 2020 (IRR 1.32, P = 0.05) compared to the same months in 2017–2019. In 2017–2019, 2134 patients presented with HCC, compared to 660 in 2020. Time-to-treatment was shorter in 2020 (median 60 vs. 70 days, P < 0.001). The percentage of patients undergoing any treatment did not differ, yet if treatment was not performed this was more commonly due to comorbidity in 2020 (52 vs. 39%, P < 0.001). No other differences were found in patient, tumor, process and treatment characteristics and survival between COVID-high and COVID-low months.

Conclusions

This study demonstrated no impact of the COVID-19 pandemic on HCC patients, despite a decrease in HCC diagnoses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularCOVID-19Liver NeoplasmsHumansNetherlandsMaleFemaleIncidenceAgedMiddle AgedAged, 80 and overAdultSARS-CoV-2Survival Analysis

Stichwörter der Autor:innen

cancercoronavirus infectionsepidemiologyliver

Autor:innen und Institutionen

  • Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Department of Interventional Radiology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Internal Medicine, Division of Medical Oncology, GROW, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • The Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.

ORCID-Profile: Alicia Furumaya

Förderung

  • ZonMw

Zitieren

APA

Furumaya, A., van Delden, O. M., de Wilde, R. F., de Vos-Geelen, J., van der Geest, L. G., & Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG) and the COVID & Cancer-NL consortium (2024). Impact of COVID-19 on Incidence, Treatment, and Survival of Patients with Hepatocellular Carcinoma in the Netherlands. Disaster Medicine and Public Health Preparedness. https://doi.org/10.1017/dmp.2024.176

Vancouver

Furumaya A, van Delden OM, de Wilde RF, de Vos-Geelen J, van der Geest LG, Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG) and the COVID & Cancer-NL consortium. Impact of COVID-19 on Incidence, Treatment, and Survival of Patients with Hepatocellular Carcinoma in the Netherlands. Disaster Medicine and Public Health Preparedness. 2024. doi:10.1017/dmp.2024.176

BibTeX
@article{Furumaya2024,
  author = {Furumaya, Alicia and van Delden, Otto M and de Wilde, Roeland F and de Vos-Geelen, Judith and van der Geest, Lydia G and Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG) and the COVID & Cancer-NL consortium, Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG) and the COVID & Cancer-NL consortium},
  title = {Impact of COVID-19 on Incidence, Treatment, and Survival of Patients with Hepatocellular Carcinoma in the Netherlands},
  journal = {Disaster Medicine and Public Health Preparedness},
  year = {2024},
  doi = {10.1017/dmp.2024.176}
}
Kostenlos starten →